Steroids and related compounds are important in disease development and prevention, via steroid receptor-mediated and receptor-independent mechanisms. Interaction of endogenous oestrogens with the oestrogen receptor has unfortunate mitogenic effects in breast cancer. However, dietary consumption of non-steroidal weak oestrogens, such as the soy isoflavone phytoestrogens genistein and diadzein, is associated with a decreased breast cancer risk. This may arise in part from the suboptimal configuration induced in the transactivation helix of oestrogen receptor-/?.
Introduction
T h e role of steroids and steroid receptors in the occurrence of disease and as targets for disease prevention is widely recognized and is currently an active area of research. For example, endogenous mitogenic oestrogens are known to play an important role in the development of breast cancer, and mutations in the oestrogen receptor are implicated in the development of tumour resistance to therapy with drugs such as tamoxifen.
Peroxisome-proliferator-activated receptor (PPAR), thyroid hormone receptor, androgen receptor and their I igands
T h e oestrogen receptors ( a and /?), androgen receptor, thyroid hormone receptor, retinoicacid receptors, retinoid-X receptors and PPAR all belong to the same family of nuclear receptors. Although many of these receptors have wellcharacterized physiological ligands e.g. steroids, thyroxine and retinoids, 'orphan ' receptors make up more than half of this gene family. Frequently, these receptors are likely to be important in development and gene regulation, but are termed 'orphan ' receptors because they have not yet been associated with a physiologically relevant ligand
[I]. T h e PPAR is one such 'orphan' receptor.
PPARs may be involved in a number of chronic diseases, including diabetes, obesity, atherosclerosis and cancer [2]. There are three known human PPAR subtypes, a, y and 6 , and these are associated with selective ligands and show distinct tissue distributions. Some ligands are common to all three PPAR isoforms, and include polyunsaturated fatty acids, and probably oxidized fatty acids [2] . PPARy regulates adipogenesis and mediates the action of thiazolidinediones, which are used pharmaceutically for the treatment of Type I1 diabetes, because they sensitize tissues to insulin [l-31. PPARy mutants have been found in subjects with severe insulin resistance. The PPARy mutants are transcriptionally impaired as a result of altered ligand binding and co-activator recruitment, and analogous to resistance to thyroid hormone, they inhibit the function of wild-type PPARy when co-expressed [3] . Resistance to 0 n thyroid hormone can occur as a result of mutations in the thyroid hormone receptor, which alter ligand binding and may also influence co-activator interaction [3] . Mutant receptors may also incorporate a co-repressor, resulting in a lack of transcription (negative regulation). Most mutations in the thyroid hormone receptor cluster around the ligand-binding domain (this is a hydrophobic cavity). Other ' orphan ' receptors include constitutive androstane receptor$ (CAR-P), which binds DNA as a heterodimer with the retinoid-X receptor, and activates gene transcription in a constitutive manner; in contrast with classical nuclear receptors, the constitutive activity of CAR$ results from a ligand-independent recruitment of transcriptional co-activators [4] .
Androgens are steroid hormones important for normal reproduction function in the adult male, in addition to playing a key role in male differentiation during development. Androgens exert their actions mostly via the androgen receptor. Important domains of this receptor include a DNA-binding domain flanked by a C-terminal ligand-binding domain and an N-terminal domain, which plays an important role in transcription. Androgen receptor structure and function is sensitive to alterations in amino acid repeat lengths in the N-terminal domain [S] . Functional and structural analysis of the androgen receptor has been carried out in a disease state termed Kennedy's disease [ 51.
Oestrogens, phytoestrogens and oestrogen receptors
Oestrogens play a vital role in the growth, development and homoeostasis of oestrogen responsive tissues. T h e oestrogen receptor mediates the biological activity of oestrogens and is a ligandinducible nuclear transcription factor : oestrogen binds to the ligand-binding domain of the oestrogen receptor, resulting in either the activation or repression of target genes [6] . Phytoestrogens, such as the soya isoflavones genistein and daidzein, are plant-derived non-steroidal oestrogen mimics that are being extensively investigated to determine their therapeutic potential, particularly in disease prevention [7] . Breast and prostate cancer is much less prevalent in FarEastern countries, where there is an abundance of soya phytoestrogens in the diet, compared with Western ones. Emigration of people from Pacific Rim countries to the U.S.A. has been shown to increase their risk of breast and prostate cancer [8] .
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These changes in breast and prostate cancer risk have been mostly attributed to change to a lowsoya Western diet. In countries such as Japan, Korea, China and Taiwan, the mean daily intake of soya products has been estimated to be in the range of 10-50 g compared with only 1-3 g in the U.S.A. [9] .
T h e phytoestrogen family includes the lignans and members of the flavonoid family, such as the isoflavonoids; also some of the flavones, flavanones, chalcones, coumestans and stilbenes [lo] . Isoflavonoids include the isoflavones genistein and daidzein, which occur mainly as the glycosides genistin and daidzin respectively, in soya beans and, consequently, in a wide range of soya-derived foods and, to a lesser extent, in other legumes [ l l ] . Some alcoholic beverages such as beer contain significant amounts of isoflavonoids Daidzin and genistin are hydrolysed in the large intestine (by the action of bacteria) to release genistein and daidzein. Daidzein can be metabolized in the large intestine by bacteria to form the isoflavan equol (oestrogenic) or O-desmethylangolensin (non-oestrogenic), whereas genistein is metabolized to the non-oestrogenic p-ethyl phenol. Inter-individual variation in ability to metabolize daidzein to equol could thus influence the potential health protective effects of soya isoflavones. Plasma isoflavonoid levels in Japanese and Finnish men have been measured, and the means of the total daidzein, genistein, O-desmethylangolensin and equol levels of these men were approximately 17-fold, 44-fold, 33-fold and 55-fold higher for the Japanese subjects compared with the Finnish ones [13] . In post-menopausal Australian women following consumption of soya flour, mean plasma levels of daidzein and equol of 68 ng/ml and 31 ng/ml respectively were observed [14] . Interestingly, only 33 of subjects were able to metabolize daidzein to equol [14] . T h e bioavailabilities of genistein and daidzein are similar (despite differences in urinary excretion, as shown by the approximately equal areas under their plasma concentration-time curves) [15] . A variable metabolic response to isoflavones has been shown for subjects following consumption of soya flour ; urinary excretion concentrations of genistein, daidzein, equol and O-desmethylangolensin were increased 8-fold, 4-fold, 45-fold and 66-fold respectively, compared with baseline levels [16] . Great interindividual variation in metabolic response was reported, with the peak levels of equol showing the most variation [16] . In [121.
healthy male and female subjects, where diets high or low in isoflavones (textured soya protein product containing 56 mg/day or 2 mg/day respectively) were each consumed for 17 days separated by a 25-day washout period, considerable interindividual variation in metabolic response was found [17] . In addition, the good equol excretors (36 yo of subjects) consumed significantly less fat and more carbohydrate (also greater amounts of non-starch polysaccharide : NSP) compared with the poor equol excretors [ 171.
T h e bioavailability of soya isoflavones has been shown to depend on the gut microflora [18] . Metabolism by the gut microflora is an important factor influencing the disposition of chemicals in the gut, and can result in activation of substances to more biologically active products. T h e presence of different populations of microflora in the human gut may influence the bioavailability of soya isoflavone phytoestrogens, and studies concerning this are currently in progress. In particular, the metabolism of daidzein to equol by certain types of gut bacteria has important implications.
T h e selective oestrogen receptor antagonist raloxifene (structurally related to the anticancer drug tamoxifen [19] ) can inhibit the mitogenic effects of oestrogen in reproductive tissues, while maintaining the beneficial effects of oestrogen in other tissues. T h e crystal structures of the ligandbinding domain of the oestrogen receptor complexed with either 178-oestradiol or with raloxifene have been reported [20] , thus providing structural evidence for the mechanisms of oestrogen receptor agonism and antagonism. A combination of specific polar and non-polar interactions enables the oestrogen receptor to selectively recognize and bind 178-oestradiol with great affinity. T h e oestrogen receptor is the only steroid receptor able to interact additionally with a large number of non-steroidal compounds, including phytoestrogens and environmental and drug xenoestrogens (and their metabolites), which frequently show a structural similarity to the steroid nucleus of oestrogen. In particular, a phenolic ring analogous to ring A in oestradiol is required and these structural features enable them to bind to oestrogen receptors to elicit responses ranging from agonism to antagonism of the endogenous hormone-ligand [21] .
Originally, it was accepted that only one oestrogen receptor existed (the classical oestrogen receptor, ERa). This is in contrast with other members of the nuclear-receptor superfamily where multiple forms have been found. A separate sub-type, termed oestrogen receptor / 3 (ERB) has subsequently been identified in cDNA libraries from rat prostate and ovary tissues [22] . ERP shows a different tissue distribution from ERa. ERB was first reported to be strongly expressed in ovary, uterus, brain, bladder, testis, prostate and lung [23] . Expression of ERB appears to occur at different sites in the brain from ERa [23] . Evidence has now been found for the presence of ERP in normal human breast tissue [24] . ERP has also been found to be expressed in both bone [25] and the cardiovascular system [26] . Furthermore, in the rat carotid injury model, following endothelial denudation of rat carotid artery, ERa is expressed at a low level, whereas the expression of ERB increases by more than that 40-fold and treatment of ovariaectomized female rats with genistein provides a similar dose-dependent vasculoprotective effect in this model to that observed with 178-oestradiol [26] .
Although genistein is a much better ligand for ERB than for the ERa (20-fold higher binding affinity) [23] , it can also act as an oestrogen agonist via both ERa and ER/3 in some test systems [27] . However, genistein also behaves as a partial oestrogen agonist in human kidney cells transiently expressing ERB, suggesting that it may be a partial oestrogen antagonist in some cells expressing ERP [28] . Furthermore, although genistein binds to the ligand-binding domain of ERP in a manner similar to that observed for 178 oestradiol, in the ERpgenistein complex, the AF-2 helix (H12) does not adopt the normal agonisttype position, but instead takes up a similar orientation to that induced by ER antagonists such as raloxifene [29] . This sub-optimal alignment of the transactivation helix is in keeping with the reported partial agonist activity of genistein in ER8 [29] .
Many other potentially beneficial mechanisms of action for phytoestrogens and genistein in particular have been suggested in addition to those mediated through the oestrogen receptor. These include : (i) inhibition of DNA topoisomerases [30] ; (ii) inhibition of cell cycle progression [31]; (iii) inhibition of angiogenesis [32] (iv) tumour invasiveness [33] ; (v) inhibition of enzymes involved in oestrogen biosynthesis [34] ; (vi) effects on the expression of the DNA transcription factors c-Fos and c-Jun [35] , and reactive oxygen species [36] ; (vii) oxidative membrane damage [37] ; and (viii) oxidative damage in wiwo [38] (ix) by the transforming growth factor-8 (TGFB) action [3 1,391 . However, many flavonoids, such as the flavonol quercetin and also the isoflavone genistein, have been shown to inhibit the action of enzymes such as sulphotransferases important for inactivating the endogenous oestrogens implicated in breast cancer [42] , suggesting that further human studies to gain a complete picture of all the biological actions of isoflavones in vivo are clearly required.
Oxytocin and the oxytocin receptor
In contrast with the steroid hormones and their receptors already considered, oxytocin is a nonapeptide hormone that induces uterine contractions and may contribute to the onset of labour and parturition. T h e steroid hormone progesterone is vital for establishing and maintaining pregnancy in mammals. Uterine quiescence is maintained by progesterone by decreasing uterine 0 200 I Biochemical Society sensitivity to oxytocin. Classically, it is considered that steroid hormones, such as progesterone, act at a genomic level by binding to nuclear receptors and modulating the expression of target genes. It is of considerable relevance therefore that the function of the oxytocin receptor (a member of the G-protein-coupled receptor family) has been reported to be inhibited by direct binding of progesterone [43] . This work appears to provide the first evidence for a direct interaction between a steroid hormone and a G-protein-coupled receptor, and delineated a new level of 'cross-talk' between the peptide-hormone and steroidhormone signalling pathways [43] . Subsequently, however, other research groups have been unable to repeat this finding [44] . Furthermore, although there is experimental evidence to suggest that, in humans, rats and ruminants, sex steroids are involved in regulating the genes for both oxytocin and the oxytocin receptor, oestrogen action appears to be indirect for both of these genes [44] .
Conclusions
In conclusion, further studies are clearly needed to elucidate the precise molecular basis for the action of related compounds and their receptors in disease and, ultimately, in disease prevention. It is predicted that a combination of human intervention studies and the techniques of proteomics and functional genomics [45] will be particularly helpful in achieving this aim. 
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